louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03687177: Visual Cue as Prevention of Pulmonary Infection Under Mechanical Ventilation
Official title: Visual Cue as Prevention of Pulmonary Infection Under Mechanical Ventilation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pulmonary Infection
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2018-09-27
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Nosocomial pneumonia is the third causes of nosocomial infection. In intensive care unit, their incidence is even higher, of the order of 10 to 30% in patients with invasive mechanical ventilation (IMV). One of the main mechanisms behind VAP (Ventilator-Associated Pneumonia) is the passage of germs colonizing the oropharynx to the subglottic airways. The presence of a nasogastric tube, immobilization, and strict dorsal decubitus increase the risk of colonization of the tracheobronchial tree and pneumonia in these patients. To reduce the incidence of VAP, several strategies have been developed in intensive care to try to control these different risk factors. These sets of measures, also called "bundle" systematically include the control of the elevation of the patient's head more than 30 °. Nevertheless, the strict and permanent control of the elevation of the patient's head is difficult to obtain. One of the reasons that may explain the difficulty of ensuring a correct elevation is the absence of visual cues that are easy to obtain on the beds of patients. An easily identifiable visual cue at the head of the bed would probably provide a satisfactory elevation (greater than 30 °) in patients intubated in intensive care. Our hypothesis is that the addition to the head of the patient's bed of a visible mark that is easily visible and easily interpretable by all the nurses will improve the elevation of the head of the patients in intensive care.


Eligibility criteria: Inclusion Criteria:

- Patient admitted to intensive care with invasive mechanical ventilation more than two days

Exclusion Criteria:

* Pregnancy
* Spinal trauma
* Brain trauma

Primary outcomes:
measure: Measurement of the angle of elevation of the head of patients with invasive mechanical ventilation
timeFrame: 3 times a day
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT01214577: Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
Official title: A Phase 2a, Multi-Centre, Single Arm Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin on the Face
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Photo-damage
Keywords: PEP005
Peplin
Photo-damage
Lead sponsor: Peplin
Sponsor class: INDUSTRY
First posted: 2010-10-05
Enrollment: 24
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is primarily designed to evaluate the safety and tolerability of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face. The secondary endpoint is to determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.


Eligibility criteria: Inclusion Criteria

1. Male and female patients aged 30 to 65 years.
2. Female patients must be of either:

   * Non-childbearing potential, provided there is a laboratory confirmed serum follicle stimulating hormone (FSH) level ≥ 40mIU/ml or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus); or
   * Childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy.
3. Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures, including any alteration of medications in preparation for study entry.
4. Patient has agreed to allow photographs of the selected treatment area to be taken and used as part of the study data package.

Exclusion Criteria

1. Known sensitivity or allergy to any of the ingredients in PEP005 (ingenol mebutate) Gel.
2. Current enrolment or participation in a clinical research study within 30 days of entry into this study.

Primary outcomes:
measure: To evaluate the safety of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face.
timeFrame: Day 43
Secondary outcomes:
measure: To determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.
timeFrame: Day 43
Other outcomes:
Locations:
city: Benowa
country: Australia
facility: The Skin Centre
state: Queensland
city: Woolloongabba
country: Australia
facility: Specialist Connect
state: Queensland
Study officials:
References:
Clinical trial NCT01078077: The Impact of a Topical Vasodilating Cream on Female Sexual Experience
Official title: The Impact of a Topical Vasodilating Cream (When Applied to the Clitoris) on the Female Sexual Experience Using a Standard 7 Part Female Sexual Dysfunction Questionnaire
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Female Sexual Dysfunction
Keywords: healthy females ages twentyfive through sixty
Lead sponsor: East Suburban Ob Gyn
Sponsor class: OTHER
Collaborators: name: West Penn Allegheny Health System
First posted: 2010-03-02
Enrollment: 200
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sexually active females from ages 25 to sixty not on SSRI's without neurologic disease able sign and understand informed consent

Brief summary: The purpose of this study is to determine if a topical vasodilating cream will improve female sexual experience.

Detailed description: To determine in a placebo controlled double blinded study whether a topically applied vasodilating cream will improve the female sexual response as measured by a standard female sexual dysfunction questionnaire

Eligibility criteria: Inclusion Criteria:

* Healthy females ages 25 to sixty sexually active

Exclusion Criteria:

* Neurologic disease, on SSRI's,advanced diabetes, non sexually active, mentally incompetent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Monroeville
country: United States
facility: East Suburban Obgyn
state: Pennsylvania
city: Monroeville
country: United States
facility: West Penn Allegheny Health Center
state: Pennsylvania
city: Monroeville
country: United States
facility: West Penn Hospital Forbes Campus
state: Pennsylvania
Study officials:
affiliation: east surburban obgyn
name: michael j pelekanos, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05394077: Effect of Active Release Technique and Abdominal Drawing-Maneuver on Pain and Quality of Life in Patients With Chronic Low Back Pain
Official title: Effect of Active Release Technique and Abdominal Drawing-Maneuver on Pain and Quality of Life in Patients With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2022-05-27
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To determine the effect of active release technique and abdominal drawing in maneuver on pain and quality of life in patients of chronic low back pain.


Eligibility criteria: Inclusion Criteria:

* Patient with hamstring tightness\[9\]
* Subjects with pain between 4 and 7cm on visual analogue scale\[18\].
* Subjects having 20-40 age group are included in this study\[11\]
* Patients having pain for more than 3 month of mild-moderate intensity\[9\]

Exclusion Criteria:

* Patients with any spine injury\[11\]
* Lumber intervertebral disc fracture\[11\]
* Patients having any surgical history of spine\[11\]
* Spinal stenosis\[11\]

Primary outcomes:
measure: Abdominal Drawing-Maneuver on Pain and Quality of Life in Patients With Chronic Low Back Pain
timeFrame: 6 Months
Secondary outcomes:
measure: Active Release Technique in Patients With Chronic Low Back Pain
timeFrame: 6 Months
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Ibrahim PT Clinic Lahore Zohaib Physiotherapy Clinic, Farooq Abad
Study officials:
References:
Clinical trial NCT01184677: ProSeal Laryngeal Mask Airway (LMA) Size 3 vs 4 in Non-paralyzed Female Patients
Official title: Comparison of the Size 3 ProsealTM Laryngeal Mask Airway Versus Size 4 in Anaesthetized, Non-paralyzed Women: A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oropharyngeal Injury
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2010-08-19
Enrollment: 154
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators hypothesize that ProSeal laryngeal mask airway (PLMA) of smaller size would reduce the incidence of mucosal injury.

Detailed description: The ProSealTM laryngeal mask airway (PLMA; Laryngeal Mask Co. Limited, Mahe, Seychelles) is a laryngeal mask device with an added dorsal cuff to improve the seal and a drainage tube to prevent aspiration and gastric insufflations(Brain, Verghese et al. 2000).Despite its utility, there are complications associated with PLMA insertion such as sore throat and mucosal injury including oropharyngeal blood.

The purpose of this randomized controlled study is to determine if size 3 PLMA would induce less mucosal damage indicated by blood on the cuff than size 4 in non-paralyzed female patients. The secondary objective of this study is to compare insertion time, number of attempts, oropharyngeal leak pressure, hemodynamic variables, and incidence of complications with size 3 and 4 PLMA.

Eligibility criteria: Inclusion Criteria:

* female
* aged 18-80 yr
* American Society of Anesthesiologists physical status Ⅰ-Ⅱ
* scheduled to undergo short outpatient gynecological procedures using ProSealTM LMA (PLMA) for anesthesia

Exclusion Criteria:

* a known or predicted difficult airway
* recent sore throat
* mouth opening less than 2.5 cm
* body mass index \> 35 kg/m2
* at risk of aspiration.

Primary outcomes:
measure: blood on the ProSeal LMA
timeFrame: from the start of ProSeal LMA insertion until the end of the anesthesia (around 30min , mostly less than 60min)
Secondary outcomes:
measure: hemodynamic variables
timeFrame: from induction of anesthesia until immediately after the Proseal LMA insertion
measure: insertion time
timeFrame: from grasping the Proseal LMA until an effective airway is established
measure: seal pressure
timeFrame: after successful insertion of Proseal LMA
measure: other intraoperative complications
timeFrame: from successful insertion of PLMA until the end of the anesthesia
measure: postoperative complications
timeFrame: from removal of Proseal LMA until discharge from recovery room
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Mihyun Kim, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01967277: A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Official title: A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Androgenetic Alopecia
Lead sponsor: Capillus, LLC
Sponsor class: INDUSTRY
First posted: 2013-10-22
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will acquire data on hair growth of the head that is the result of treatment with a non-heat generating, laser product. This data will come from counting of terminal hairs before treatment begins and after treatment is completed. The treatment regime is every other day for 16 weeks.

Detailed description: The purpose of this study is to evaluate the efficacy of Low Level Laser Therapy product that is configured in the novel design of a baseball cap, for promoting hair growth in females diagnosed with genetic hair loss/female pattern hair loss.

Eligibility criteria: Inclusion Criteria:

Diagnosis of Androgenetic Alopecia / Female Pattern Hair Loss Fitzpatrick skin phototypes of I - IV Ludwig-Savin Hair Loss scale I - II In overall good health as determined by the physician investigator Active hair loss within the last 12 months Willingness to refrain from using all other hair growth products or treatments -

Exclusion Criteria:

Photosensitivity to the specific wavelength of light - 650 nanometers. Malignancy in the target treatment area Other forms of alopecia of the head Past medical history of a collagen-vascular disease, thyroid disease or other cutaneous or systemic disease that seriously affects the scalp.

In willingness to remove hair replacement products during the 16 weeks of therapy.

Using any medications deemed to inhibit hair growth as determined by the physician investigator.

-

Primary outcomes:
measure: Percentage Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects.
timeFrame: baseline and 17 weeks
measure: Absolute Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects.
timeFrame: baseline and 17 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Great Neck
country: United States
facility: Bodian Dermatology
state: New York
city: Woodbury
country: United States
facility: Center for Aesthetic Dermatology
state: New York
Study officials:
affiliation: NST Consulting, LLC
name: Raymond R. Blanche, BA
role: STUDY_DIRECTOR
References: